



Forward-looking statements

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but that may not prove to be accurate. By their nature, forward-looking statements involve risk and uncertainty. Consequently, the company cannot guarantee their accuracy and their completeness, and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of.


For additional information concerning important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the Autorité des Marchés Financiers.

Any forward-looking statement speaks only as of the date on which it is made, and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.



The first 9 Months 2022 Important facts

9M 2022



Revenue

- Growth continue in Q3
- All operating divisions contributed to 9M organic growth
- Sales momentum for Cegedim Santé

Cegedim Santé

- Strategic partnership with 3 social protection groups representing 25 million beneficiaries in France
- Reserved capital increase of €65 million
- Development plan launch



The first 9 Months 2022 Important facts

Mesdocteurs | May 2022

A leader in telehealth and a pioneer in 24/7 telemedicine

Laponi | June 2022

An SaaS innovative solution for managing absenteeism in real time

SEDIA | July 2022


Tracking software for medical instrumentation since 1985

Clinityx | July 2022

Innovative data valorization model with Real world data and matching expertise




3Q 2022 Revenue up 5.6 % L.f.I





9M 2022 Revenue up 5.9% L.f.I





Software & services

55.1%

of 9M 2022 Group revenue


€220.8m

Revenue


+4.4%

+€9.3m

3Q 2022



9M 2022



Comments

- All of the division's activities turned in solid performances with the exception of the healthcare professional computerization business in the UK which, as expected, is still gearing up for recovery.
- Start of Cegedim Santé sales momentum





Flow

16.6%
of 9M 2022 Group revenue

€66.7m
Revenue

+8.5%
+€5.2m



Comments

- The process digitalization and digital data flow business experienced strong growth in France.
- The clear recovery seen in Germany and the UK in the first semester continued in the third quarter.
- The healthcare flow business related to healthcare reimbursements in France also grew in the quarter.





Data & marketing

18.2%
of 9M 2022 Group revenue

€72.8m
Revenue

+9.4%
+€6.2m



Comments

- Data business keep up good sales momentum with a third quarter growth in line with H1 growth.
- Digital communication solutions for French pharmacies, despite a third quarter impacted by a perimeter effect compared to 3Q 2021, is still growing with double digit growth after 9M in 2022.




BPO

9.6%
of 9M 2022 Group revenue


€38.4m
Revenue

+11.8%
+€4.0m

3Q 2022



9M 2022



Comments

- The business of providing services for insurance companies and mutual insurance providers was stable in the first quarter and posted double-digit growth in the second and third quarter.
- Growth in BPO services for HR departments--already in double digits in H1--keep up in the third quarter.



Outlook

Outlook

- The Group is **confident** it can **grow revenues**
- There is a **delay of several months** between **wage increases** and the **annual increase in product prices resulting from indexation**, for example the Syntec index in France.
- The **negative impact** of that delay, combined with Cegedim Santé development plan launch, will be a **headwind for 2022 recurring operating income⁽¹⁾**.


(1) See 2021 Universal Registration Document Chapter 4 "Consolidated Financial Statements" section 4.6 Note 2 on Alternative performance indicators.

2022 Outlook



FY 2022 Revenue

+ 5 % LFL vs FY 2021



2022 Recurring operating income ⁽¹⁾



Disclosure: Based on currently available information. The Group does not expect to make any significant acquisitions in 2022. And lastly, the Group does not provide earnings estimates or forecasts.



9M 2022 Summary

9M 2022 Revenue

- Increased by 5.9% L.f.I
- Growth maintain speed in the 3Q
- All operating division contributed to growth

Cegedim Santé

- Strategic partnership with 3 social protection groups representing 25 million beneficiaries in France
- Reserved capital increase of €65 million
- Development plan

Bolt-on acquisition

- Mesdocteurs
- Laponi
- SEDIA
- Clinityx

Innovation

- Continuing investment in innovation

Outlook

- Delay of several months between wage increases and the annual increase in product prices resulting from indexation
- Cegedim Santé development plan
- Recurring operating income expected to be down



Significant events post september 30th

- **Allianz contract**

Allianz France and [Cegedim Insurance Solutions](#)—a major provider of software solutions and services for the personal protection insurance sector—have signed a 15-year strategic partnership under which Allianz will outsource to [Cegedim Insurance Solutions](#) the management of insurance policy portfolios in the Group Health, Individual Health, and Group Personal Protection segments in France. The deal covers 1.3 million beneficiaries.

As part of the partnership, the Allianz France staff that currently perform these duties will be transferred to [Cegedim](#).

This contract will impact the Group figures starting 2023.




2023 Financial agenda


January 26

after the market closes

FY 2022
REVENUE



Q&A session



Addendum 9M 2022 Revenue



9M Revenue 2022

	Third quarter		Change Q3 2022 / 2021		First 9 months		Change 9M 2022 / 2021	
<i>in millions of euros</i>	2022	2021	Reported	Like for like ⁽¹⁾⁽²⁾	2022	2021	Reported	Like for like ⁽¹⁾⁽²⁾
Software & services	75.2	71.3	+5.5%	+3.7%	220.8	211.5	+4.4%	+3.3%
Flow	21.5	19.8	+8.8%	+8.8%	66.7	61.5	+8.5%	+8.4%
Data & Marketing	22.8	21.8	+4.5%	+3.7%	72.8	66.5	+9.4%	+9.1%
BPO	13.0	11.4	+13.6%	+13.6%	38.4	34.4	+11.8%	+11.8%
Corporate and others	0.8	0.5	+41.1%	+41.1%	2.1	2.0	+2.5%	+2.5%
Cegedim	133.3	124.8	+6.7%	+5.6%	400.8	376.0	+6.6%	+5.9%

(1) At constant scope and exchange rates.

(2) The positive currency impact of 0.2% was mainly due to the pound sterling. The positive scope effect of 0.5% was attributable to the first-time consolidation of [Kobus Tech](#), [Mesdocteurs](#), [Laponi](#) and [Clinityx](#).




9M Revenue 2022 - by Division

	Third quarter		Change Q3 2022 / 2021		First 9 months		Change 9M 2022 / 2021	
<i>in millions of euros</i>	2022	2021	Reported	Like for like	2022	2021	Reported	Like for like
Cegedim Santé:	18.5	15.4	+20.0%	+12.6%	50.3	45.9	+9.5%	+5.9%
Insurance, HR, Pharmacies and other services	44.7	42.3	+5.7%	+5.5%	134.5	126.3	+6.5%	+6.4%
International businesses	12.0	13.6	(11.6)%	(11.6)%	36.0	39.3	(8.4)%	(9.8)%
Software & Services	75.2	71.3	5.5%	3.7%	220.8	211.5	4.4%	3.3%
e-business	12.9	11.3	+13.5%	+13.6%	40.1	35.3	+13.5%	+13.4%
Third-party payer	8.6	8.4	+2.5%	+2.5%	26.6	26.2	+1.7%	+1.7%
Flow	21.5	19.8	8.8%	8.8%	66.7	61.5	8.5%	8.4%
Data	14.3	13.0	+10.1%	+8.7%	40.4	37.2	+8.5%	+8.1%
Marketing	8.5	8.8	(3.7)%	(3.7)%	32.4	29.3	+10.5%	+10.5%
Data & Marketing	22.8	21.8	4.5%	3.7%	72.8	66.5	9.4%	9.1%
Insurance BPO	8.1	7.1	+13.8%	+13.8%	23.7	21.8	+9.0%	+9.0%
HR BPO	4.9	4.3	+13.3%	+13.3%	14.7	12.6	+16.5%	+16.5%
BPO	13.0	11.4	13.6%	13.6%	38.4	34.4	11.8%	11.8%



9M Revenue 2022 – by geographic area

Geographic area	Third quarter		First 9 Months	
	France	Excl. France	France	Excl. France
%				
Software & services	84,0%	16,0%	83,7%	16,3%
Flow	92,2%	7,8%	92,5%	7,5%
Data & Marketing	97,4%	2,6%	97,6%	2,4%
BPO	100,0%	0,0%	100,0%	0,0%
Corporate & others	99,4%	0,6%	99,6%	0,4%
Cegedim	89,3%	10,7%	89,3%	10,7%



Thank you for your attention

For any additional information
Investor.relations@cegedim.com

www.cegedim.com/finance

Download our mobile app Cegedim IR in iOS and Android and follow us on



Public company with share capital of 13,336,506.43€ | 137 rue d'Aguesseau 92100 Boulogne-Billancourt